For the quarter ending 2026-03-31, KNSA made $214,266K in revenue. $21,952K in net income. Net profit margin of 10.25%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 214,266 | 171,088* | 180,855 | 156,797 |
| Cost of goods sold | 20,796 | 19,383* | 20,257 | 18,603 |
| Collaboration expenses | 75,577 | 55,958* | 63,307 | 52,418 |
| Research and development | 27,475 | 32,475* | 24,166 | 18,753 |
| Selling, general and administrative | 61,151 | 52,322* | 49,104 | 46,863 |
| Total operating expenses | 184,999 | 160,137* | 156,834 | 136,637 |
| Income (loss) from operations | 29,267 | 10,951* | 24,021 | 20,160 |
| Other income | 3,414 | 2,868* | 3,136 | 2,717 |
| Income (loss) before income taxes | 32,681 | 13,818* | 27,157 | 22,877 |
| Provision for income taxes | 10,089 | 9,213* | 8,722 | 5,045 |
| Net income (loss) | 22,592 | 4,605* | 18,435 | 17,832 |
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | -640 | 123 | -102 | 112 |
| Total other comprehensive income (loss) | -640 | 123* | -102 | 112 |
| Total comprehensive income (loss) | 21,952 | 4,728 | 18,333 | 17,944 |
| Basic EPS | 0.3 | 0.063 | 0.25 | 0.24 |
| Diluted EPS | 0.27 | 0.06 | 0.23 | 0.23 |
| Basic Average Shares | 76,516,535 | 74,449,396 | 74,714,846 | 73,438,530 |
| Diluted Average Shares | 82,409,703 | 78,959,608 | 80,035,400 | 77,942,082 |
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)